title: CD147 and matrix metalloproteinase-2 protein expression as significant prognostic factors in esophageal squamous cell carcinoma.
abstract: BACKGROUND
  The authors investigated whether the presence of matrix metalloproteinase-2 (MMP-2) and its inducer, CD147, in cancerous esophageal lesions and surrounding tissue might help to predict patient prognosis.
  
  
  METHODS
  Tissue samples from 101 patients with esophageal squamous cell carcinoma were stained with anti-CD147 and anti-MMP-2 antibodies for immunohistochemical analysis.
  
  
  RESULTS
  CD147 was expressed in cancerous and dysplastic lesions, but not in normal tissue. In contrast, MMP-2 was detected mainly in normal interstitial tissue adjacent to cancerous lesions, but it was detected also in cancerous lesions in some patients. Pathologic findings demonstrated that the intensity of MMP-2 staining in normal tissue was associated positively with the depth of tumor infiltration and the stage of disease, whereas MMP-2 staining in cancerous tissue was associated positively with vascular and lymphatic vessel invasion as well as with immature differentiation of cancer cells. Using a proportional hazard model, including information on CD147 staining patterns within cancerous lesions along with clinical cancer staging, improved the accuracy of predicting patient prognosis.
  
  
  CONCLUSIONS
  These results suggested that measurement of CD147 and MMP-2 expression with simple immunohistochemical staining may enhance further the understanding of the pathophysiology of invading tumor cells and, when used in combination with cancer staging, may increase the ability of investigators to predict prognosis in patients with esophageal squamous cell carcinoma.
authors.affiliation: Department of Surgery, Jikei University School of Medicine, Tokyo, Japan.
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Ishibashi
authors.forename: Tomoe
authors.initials: T
authors.lastname: Matsumoto
authors.forename: Mikio
authors.initials: M
authors.lastname: Niwa
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Suzuki
authors.forename: Nobuo
authors.initials: N
authors.lastname: Omura
authors.forename: Nobuyoshi
authors.initials: N
authors.lastname: Hanyu
authors.forename: Koji
authors.initials: K
authors.lastname: Nakada
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Yanaga
authors.forename: Kyosuke
authors.initials: K
authors.lastname: Yamada
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Ohkawa
authors.forename: Makio
authors.initials: M
authors.lastname: Kawakami
authors.forename: Mitsuyoshi
authors.initials: M
authors.lastname: Urashima
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000595:Amino Acid Sequence; D015703:Antigens, CD / Q000032:analysis*; D000951:Antigens, Neoplasm / Q000032:analysis*; D051926:Basigin; D002294:Carcinoma, Squamous Cell / Q000737:chemistry* / Q000401:mortality / Q000473:pathology; D018572:Disease-Free Survival; D004938:Esophageal Neoplasms / Q000737:chemistry* / Q000401:mortality / Q000473:pathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000032:analysis*; D008875:Middle Aged; D008969:Molecular Sequence Data; D011379:Prognosis; D016016:Proportional Hazards Models
chemical_list: D015703:Antigens, CD; D000951:Antigens, Neoplasm; C497886:BSG protein, human; D051926:Basigin; D020778:Matrix Metalloproteinase 2